Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

123.30 +0.19 (+0.15%)
Streaming Delayed Price Updated: 12:59 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
From Gilead Sciences, Inc.
Via Business Wire
Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
From Gilead Sciences, Inc.
Via Business Wire
Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention
From Gilead Sciences, Inc.
Via Business Wire
Jerry Pinkas Earns Certified Probate Specialist Designation, Elevating Compassionate Real Estate Expertise for South Carolina Families
Via Get News
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
From Gilead Sciences, Inc.
Via Business Wire
Gilead Foundation Grants $6.5 Million in Commitment to STEM Education
From Gilead Sciences, Inc.
Via Business Wire
Cumberland First in Families to Host 2nd Annual Mister & Miss FIFNC Pageant
Via Get News
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at LSX World Congress 2025
Via Investor Brand Network
Topics Intellectual Property
2024 R&D Spending and Intensity Benchmarks
Via PRLog
Topics Supply Chain
Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy
From Gilead Sciences, Inc.
Via Business Wire
European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
NAFA Publishes New Fleet Safety Guidebook Aimed at Developing Safety-First Culture in all Organizations
Comtex News Network, Inc. is a content specialist offering actionable news distribution, global syndication, and traffic for your content 
Via News Direct
Gilead Sciences Announces Second Quarter 2025 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025
From Gilead Sciences, Inc.
Via Business Wire
NAFA Publishes New Fleet Safety Guidebook Aimed  at Developing Safety-First Culture in all Organizations
Comtex News Network, Inc. is a content specialist offering actionable news distribution, global syndication, and traffic for your content 
Via News Direct
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
Expanding the Preventive Care Frontier: Dr. Reddy’s Launches Sanofi’s Beyfortus® in India
Via AB Newswire
Topics Death
GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025
From Gilead Sciences, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
From Gilead Sciences, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.